Gastrointestinal stromal tumor is characterized by a gain of function mutation of KIT gene and the expression of c-kit protein, but in 5% of cases, c-kit expression is negative although histological findings of gastrointestinal stromal tumor are most suspicious. The existence of c-kit-negative gastrointestinal stromal tumors points to the need of additional markers for making the diagnosis. In this study, we studied the expression of PKCh and correlated their expression with other immunohistochemical profiles of gastrointestinal stromal tumors and evaluated their usability as a diagnostic marker. For this purpose, 220 gastrointestinal stromal tumors were immunohistochemically stained for PKCh, c-kit, CD34, a-smooth muscle actin and S-100 protein. Additionally, genetic studies of KIT and PDGFRA genes were performed using c-kit-negative or PKCh-negative cases. All the 220 masses were either PKCh-positive or c-kit-positive. PKCh was positive in 212 (96%) cases and c-kit was positive in 216 (98%) cases in the cytoplasm of tumor cells with a diffuse staining pattern. Out of 212 PKChpositive GISTs, 208 (98%) cases were c-kit-positive, 174 (82%) cases were CD34-positive, 62 (29%) cases were SMA-positive and S-100 protein was positive in 54 cases (26%). Genetic analyses on eight PKCh-negative cases showed exon 11 mutations of KIT gene in four cases. Two PKCh-positive and c-kit-negative GISTs showed mutations of PDGFRA gene. Our study shows that PKCh is a useful marker and it may play a role in the development of gastrointestinal stromal tumors. Together with c-kit, PKCh immunostaining can be used as an important diagnostic tool in the pathologic diagnosis of gastrointestinal stromal tumors with its high specificity and sensitivity.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the digestive tract. KIT proto-oncogene, located on chromosome 4q11-21, encodes a type III receptor tyrosine kinase protein (c-kit) of the immunoglobulin supergene family. Somatic gain of function mutation of KIT in GISTs is associated with activation mutations mostly in the juxtamembrane domain at exon 11, followed by exons 9, 13 and 17, which encodes the extracellular domain and phosphotransferase domain. A minority of GISTs lack demonstrable KIT mutations, but c-kit is nonetheless activated. 1 KIT gene product, c-kit, is expressed in the interstitial cells of Cajal (ICC) and in 81-100% of GISTs regardless of the site of origin, histologic appearance and biologic behavior, and is therefore considered to be best defining feature of GISTs. [2] [3] [4] [5] [6] [7] However, c-kit expression as a diagnostic standards have several limitations. First, c-kit expression is negative in approximately 5% of GISTs with typical histologic features. These c-kit-negative GISTs are common in the stomach and frequent in the epitheliod or mixed epitheliod/spindle cell type. 8 Second, the proportion of c-kit-positive cells in GIST is usually at least 90%, but may be as low as 5-20% in occasional tumors. 2 This may account for the rare c-kit negativity in small biopsies of tumors with the morphology of a GIST. Third, c-kit is also expressed by a large number of other tumor types, such as leimyosarcoma, synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor. 9, 10 Fourth, c-kit positivity can be caused by technical artefacts such as improper dilution and immoderate antigen retrieval. 2 Recently, a gene expression study on GISTs revealed constant overexpression of protein kinase C theta (PKCy), a novel PKC isotype involved in T-cell activation, 11, 12 in skeletal muscle signal transduction, 13 and in neuronal differentiation.
14 Although PKCy expression in GISTs was confirmed in previous studies, [15] [16] [17] the number of GISTs used for these studies was small and the potential diagnostic relevance for paraffin-embedded sections was not completely evaluated. In this study, we studied the expression of PKCy in 220 GISTs and correlated their expression with the other immunohistochemical profiles of GISTs and further evaluated their usability as an additional diagnostic marker.
Materials and methods
The cases analyzed in this study were 220 GISTs, 25 All the immunohistochemical stainings were performed using primary antibodies, including rabbit polyclonal anti-human c-kit (Dako), PKCy (clone 27, BD Transduction Laboratories, 1:100), CD34 (clone Qbend10, Dako, 1:50), a-smooth muscle actin (SMA) (clone 1A4, Dako, 1:50) and S-100 protein (polyclonal, Dako, 1:1000) with DAKO EnVisiont þ System according to the manufacturer's instructions and diaminobenzidine (DAB) was used as a chromogen. For PKCy, antigen retrieval was performed using a pressure cooker and microwaves for 20 min. For the antigen retrieval of CD34, boiling the slides in citrate buffer for 10 min was performed with microwaves. For the staining of c-kit, a 1:800 dilution of the anti-c-kit antibody without antigen retrieval was selected with using a KIT mutation positive GIST as a positive control and normal smooth muscle was used as a negative control.
For the genetic analyses, 12 GISTs negative for either PKCy or c-kit were analyzed for exons 9, 11, 13 and 17 of KIT gene and for exons 10, 14 and 18 of PDGFRA gene. Genomic DNAs from both the tumors and normal tissues were extracted from the paraffinembedded tissue by standard proteinase K digestion and phenol/chloroform extraction as described previously. 18 DNA sequences of the primers and PCR conditions are described in Table 1 . PCR products were electrophoresed through 8% polyacrylamide gel with ethidium bromide to confirm the correct amplification. The amplified PCR products were diluted 1:1 in loading buffer (94% formamide, 10 mg bromophenol blue and 0.05% xylene cyanol), and denatured by heating them at 981C for 5 min. The products were next put on ice and then loaded onto a 5% SequaGel sequencing system (National Diagnostics, Atlanta, GA, USA). Electrophoresis was carried out for 90 min at a constant power of 1800 V with electrophoresis apparatus (BioRad, USA). After electrophoresis, the gels were stained with DNA silver staining kit (Bioneer, Korea). The samples showing either normal or abnormal migration bands on PCR-SSCP were purified, and both strands were directly sequenced using a BigDye Terminator v3.1 cycle sequencing kit and analyzed with an Applied Biosystems 3700 automated sequencer (Applied Biosystems, Foster City, CA, USA). Statistical analysis was carried out using SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL, USA). The Pearson correlation test was used for analysis of the results. A P-value of less than 0.05 was considered statistically significant.
Results

Clinicopathologic and Immunohistochemical Staining Results
The ages of patients ranged from 18 to 84 years (mean age: 57.4 years). Among 220 patients, 108 were males and 112 were females. The clinical stages at presentation included tumor localized within an organ in 204 cases, tumor invasion into adjacent organs in 10 cases and distant tumor metastasis in six cases. GISTs occurred in the stomach in 130 cases (59%), the jejunum and ileum in 57 cases (26%), the duodenum in 21 cases (10%), the colorectum in nine cases (4%) and the esophagus in three cases (1%). The histologic types of GISTs included the spindle cell type in 166 cases (75%), the epitheliod cell type in 20 cases (9%) and the mixed type in 34 cases (16%). The pathologic risk of aggressive behavior was very low risk in 23 cases (11%), low risk in 66 cases (30%), intermediate risk in 49 cases (22%) and high risk in 82 cases (37%).
PKCy was positive in the 212 cases (96%) having the typical histologic features of GISTs (Figure 1 ). According to the staining pattern, diffuse cytoplasmic staining was observed in 203 cases (cytoplasmic dot-like staining was found in one case), focal cytoplasmic staining was detected in two cases and weak staining was observed in seven cases. Relationship between the expression of PKCy and the other immunohistochemical markers of GISTs are described in Table 2 . Expression of PKCy according to the risk of aggressive behavior included 91% for the very low risk, 100% for the low risk, 98% for the intermediate risk and 94% for the high risk. PKCy expression was not related to the clinical stages, histologic types, degrees of cellularity and cellular atypia, the presence of necrosis, the presence of mucosal invasion, the locations of GISTs (Table 3 ) and the risks of aggressive behavior (P40.05) ( Table 4 ). All PKCy-negative GISTs were S-100 protein negative.
c-kit positivity was found in 216 cases (98%). Both PKCy and c-kit were diffusely stained in the cytoplasm and along the membrane of the tumor cells. Of the 18 cases showing prominent perinuclear dot-like staining for c-kit, one case showed the same Golgi zone-like staining for PKCy. Among the 20 epithelioid GISTs, one case was negative for PKCy and one was negative for c-kit, respectively. For the mesenchymal tumors of the gastrointestinal tract other than GIST, all the leiomyomas, inflammatory fibroid polyps, leiomyosarcomas, melanomas, inflammatory myofibroblastic tumors, desmoid-type fibromatosis, poorly differentiated carcinomas and endometrial stromal sarcoma were completely negative for PKCy while four (40%) melanomas involving the colon were positive for c-kit (Figure 2) . In four cases out of 15 schwannomas (27%), PKCy was weakly positive in the palisading Verocay body, which is characteristic to identify these tumors as schwannoma (Figure 3 ).
Genetic Analysis
Among the 12 GISTs negative for PKCy or c-kit, two c-kit-negative and PKCy-positive gastric GISTs showed mutations of PDGFRA gene at exons 14 and 18. These gastric GISTs with PDGFRA mutations were SMA and S-100 negative and one of them was CD34-positive. In seven c-kit-positive and PKCy-negative GISTs, KIT mutations were found in four out of five of the entirely sequenced cases. For one case, because of PCR failure, complete sequencing of PCR products was not available. All KIT mutations found in this study were located in exon 11 and they included WKKVV557-561C, 11 duplication 575-591 þ intron, deletion WK557-558, and point mutation of L576P. The c-kit-positive and PKCy-negative GISTs harboring KIT mutations were located in the stomach (three cases) and rectum (one case). The precise results of mutation tests for KIT and PDGFRA genes and their clinicopathologic features are described in Table 5 .
Discussion
Numerous polyclonal and monoclonal anti-KIT antibodies have been produced and used in the pathology laboratories to diagnose GISTs. Yet the KIT expression in GISTs depends on the antibodies and the staining conditions, such as antigen retrieval, dilution and the detection methods. It has often been difficult to interpret the significance of weak or focal positive c-kit staining. Moreover, there remains a small problematic group of tumors with the morphological features of GISTs, but they are without a c-kit expression. 19 Some pathologists have designated these as GIST-like tumors. In these c-kitnegative GIST cases, the pathologic diagnosis is difficult without genetic analyses. On the contrary, c-kit is also expressed by a large number of other tumor types such as synovial sarcoma, malignant fibrous histiocytoma, leiomyosarcoma and endometrial stromal sarcoma. 2, 9, 10 To overcome these problems, we studied the expression of a newly developed protein, PKCy, in 220 paraffin blocks of GISTs and we correlated their expression with the other immunohistochemical profiles and evaluated PKCy's utility as a diagnostic marker.
PKC is a serine/threonine kinase involved in the control of cell proliferation, differentiation, and motility. 20 KIT is a 145-kDa transmembrane glycoprotein that serves as the receptor for stem cell factor (SCF) and has tyrosine kinase activity. 21 Binding of SCF to KIT results in receptor homodimerization, activation of tyrosine kinase activity and the resultant phosphorylation of a variety of substrates. 22 In many GISTs, the mutant KIT isoforms demonstrated constitutive kinase activity and their kinase domains were active even in the absence of SCF. PKC controls KIT/SCFR tyrosine kinase activity and modulates the cellular responses to SCF. Recently, it has been shown that PKCy is also constitutively activated in GISTs including those which are c-kit-negative, although immunoblotting PKCy expression in these is 50% lower than in c-kitpositive GISTs. 15 Southwell et al 23 found localization of this protein in the ICCs of guinea-pig gastrointestinal tract. In the present study, we could detect weak and scattered positivity in the ICCs of human intermyenteric plexus and expression of PKCy in GISTs was 96%. Although our expression frequency of PKCy was slightly higher than that of a previous report, 17 this was related to a higher frequency of c-kit positivity and to our selection of GISTs with using strict criteria. These findings strongly support potential use of PKCy inhibitors in the treatment of GISTs.
In this study, we could find that PKCy was strongly expressed in GIST-like tumors showing typical histologic features of GISTs with negative expression of c-kit. The expression of PKCy in various locations of GISTs and their relation to the risk of aggressive behavior has not been studied. PKCy expression was not related to the locations and the pathologic risks of GISTs. Although PKCy showed focal weak reactivity in schwannomas due to its role in neuronal differentiation, PKCy expression was not present in other mesenchymal tumors of the gastrointestinal tract other than GISTs. Even in schwannomas, the expression of PKCy was limited to the Verocay body and it also served as a definite clue for the diagnosis of this tumor. In this study, 40% of the melanomas showed strong cytoplasmic staining for c-kit protein while they were completely negative for PKCy. PKCy was strongly positive in two gastric c-kit-negative GISTs with PDGFRA mutations. With its high specificity and sensitivity, PKCy immunostaining can be used as an important diagnostic tool for making the pathologic diagnosis of GISTs in the routine pathology laboratory, in addition to determining the c-kit protein expression.
For the immunohistochemistry of c-kit, most investigators have used heat retrieval with acid (citrate, pH 6.0) or alkaline buffer (EDTA, 372 mg/l, pH 8.0). We tried various conditions during setting up the staining conditions of c-kit. Epitope retrieval with citrate buffer at pH 6.0 and a dilution at 1:400 was first used. As we found a weak positive reaction in a negative control, various dilution rates ranging PKCh in gastrointestinal stromal tumors K-M Kim et al from 1:50 to 1:1600 without antigen retrieval was tried. Finally, a 1:800 dilution without antigen retrieval was selected.
In our immunohistochemistry results, we found very interesting results on the expression of CD34 in the small intestine. Unlike the relatively higher expression of CD34 in the stomach (93%), esophagus (100%) and colorectum (89%), the small intestinal GISTs showed a lower expression, that is, 57% for duodenum tumor and 47% for jejunum and ileum tumor. Miettinen et al 24 also found that among c-kit-positive GISTs, CD34 was positive in only 47% of the small intestinal GISTs. In our study, all but one CD34-positive GISTs were c-kit-positive and among 39 CD34-negative GISTs, 36 cases were c-kit-positive. These results are compatible with previous reports that CD34-positive GISTs are almost always c-kit-positive and most CD34-negative GISTs are c-kit-positive. 25 In conclusion, our results indicate that PKCy is easily detected by immunohistochemistry in paraffin blocks of GISTs and it is a very sensitive and specific supplementary marker for the diagnosis of GISTs.
